Literature DB >> 9236453

Reoxygenation of hypoxic human umbilical vein endothelial cells activates the classic complement pathway.

C D Collard1, A Väkevä, C Büküsoglu, G Zünd, C J Sperati, S P Colgan, G L Stahl.   

Abstract

BACKGROUND: Ischemia-reperfusion injury leads to the activation and endothelial deposition of complement. We investigated whether exposure of human umbilical vein endothelial cells (HUVECs) to hypoxia and/or reoxygenation activates complement and decreases HUVEC-surface expression of the C3 regulatory proteins CD46 and CD55. METHODS AND
RESULTS: HUVECs were subjected to 0, 12, or 24 hours of hypoxia (O2 = 1%) and then reoxygenated for 3 hours (O2 = 21%) in the presence of 30% human serum. C3 deposition and HUVEC-surface expression of CD46 and CD55 were evaluated by ELISA and flow cytometry. C3 deposition on HUVECs subjected to 12 or 24 hours of hypoxia followed by 3 hours of reoxygenation was significantly greater than normoxic HUVECs. Inhibition of the classic but not the alternative complement pathway during reoxygenation attenuated C3 deposition. Western blot analysis of HUVEC lysates under reducing conditions demonstrated significantly increased iC3b deposition in hypoxic/reoxygenated HUVECs compared with normoxic HUVECs. FACS analysis confirmed iC3b deposition. HUVEC-surface expression of CD46 and CD55 increases after hypoxia and/or reoxygenation.
CONCLUSIONS: We conclude that (1) hypoxia and reoxygenation of HUVECs significantly increases iC3b deposition on HUVECs, (2) C3 deposition after hypoxia and reoxygenation is largely mediated by the classic complement pathway, and (3) HUVEC-surface expression of CD46 and CD55 increases after hypoxia and reoxygenation. These data demonstrate that hypoxia and reoxygenation of human endothelial cells activates the classic complement pathway despite an increase in complement C3 regulatory proteins.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9236453     DOI: 10.1161/01.cir.96.1.326

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  21 in total

1.  Complement activation by apoptotic endothelial cells following hypoxia/reoxygenation.

Authors:  C Mold; C A Morris
Journal:  Immunology       Date:  2001-03       Impact factor: 7.397

2.  Salidroside Restores an Anti-inflammatory Endothelial Phenotype by Selectively Inhibiting Endothelial Complement After Oxidative Stress.

Authors:  Y Wang; Y Su; W Lai; X Huang; K Chu; J Brown; G Hong
Journal:  Inflammation       Date:  2020-02       Impact factor: 4.092

3.  Hypoxia-Inducible Factor-1α Regulates CD55 in Airway Epithelium.

Authors:  Pankita H Pandya; Amanda J Fisher; Elizabeth A Mickler; Constance J Temm; Kelsey P Lipking; Adam Gracon; Katia Rothhaar; George E Sandusky; Mary Murray; Karen Pollok; Jamie Renbarger; Janice S Blum; Tim Lahm; David S Wilkes
Journal:  Am J Respir Cell Mol Biol       Date:  2016-12       Impact factor: 6.914

4.  Oxidative stress and the regulation of complement activation in human glaucoma.

Authors:  Gülgün Tezel; Xiangjun Yang; Cheng Luo; Angela D Kain; David W Powell; Markus H Kuehn; Henry J Kaplan
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-05-19       Impact factor: 4.799

5.  Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver.

Authors:  L Bergamaschini; G Gobbo; S Gatti; L Caccamo; P Prato; M Maggioni; P Braidotti; R Di Stefano; L R Fassati
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

6.  Complement activation after oxidative stress: role of the lectin complement pathway.

Authors:  C D Collard; A Väkevä; M A Morrissey; A Agah; S A Rollins; W R Reenstra; J A Buras; S Meri; G L Stahl
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

7.  Ulex europaeus agglutinin II (UEA-II) is a novel, potent inhibitor of complement activation.

Authors:  R Lekowski; C D Collard; W R Reenstra; G L Stahl
Journal:  Protein Sci       Date:  2001-02       Impact factor: 6.725

8.  C1 inhibitor-mediated myocardial protection from chronic intermittent hypoxia-induced injury.

Authors:  Jinrong Fu; Furong Guo; Cheng Chen; Xiaoman Yu; Ke Hu; Mingjiang Li
Journal:  Exp Ther Med       Date:  2016-08-12       Impact factor: 2.447

Review 9.  The dual role of complement in cancer and its implication in anti-tumor therapy.

Authors:  Ioannis Kourtzelis; Stavros Rafail
Journal:  Ann Transl Med       Date:  2016-07

10.  Polyglycolic acid-induced inflammation: role of hydrolysis and resulting complement activation.

Authors:  Kathleen Ceonzo; Anne Gaynor; Lisa Shaffer; Koji Kojima; Charles A Vacanti; Gregory L Stahl
Journal:  Tissue Eng       Date:  2006-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.